Pricing Log in Create free account
Friday 6 November 2026 Export TAK’s income statement to Excel — free account

Takeda Pharmaceutical Co.

TAK Healthcare Drug Manufacturers Specialty & Generic

Takeda Pharmaceutical Co.’s revenue for fiscal 2026 (year ended March 2026) was $29.7 billion, down 1.66% from fiscal 2025.

Revenue
+1.71%
EPS
−4.35%
Free cash flow
+54.9%
Total debt
−7.28%

Quarter to September 2026, against a year earlier

21.25 0.19 +0.90%
Market cap
$67.7B
P/E
32.0×
Fwd P/E
—
Dividend yield
1.45%
F-score
4/9
Altman Z
1.03
Beneish M
−2.65
Dividend safety
25/100
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Takeda Pharmaceutical Co. (TAK) Debt to equity

Alert me on Debt to equity

Takeda Pharmaceutical Co.'s debt to equity at the end of the quarter to 30 September 2026 was 0.6×, down 0.0× from fiscal 2026 (0.7×). Over the past ten years it has ranged from 0.3× (fiscal 2015) to 1.1× (fiscal 2019); the current reading is higher than 50% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 0.0× and above the Healthcare sector median of 0.0×.

Debt to equity, annual

Embed this chart

Annual newest first

Period Debt to equity Change
FY2026 0.7× 0.92%
FY2025 0.7× (2.24%)
FY2024 0.7× (3.44%)
FY2023 0.7× (9.81%)
FY2022 0.8× (14.60%)
FY2021 0.9× (16.90%)
FY2020 1.1× (3.27%)
FY2019 1.1× 127.96%
FY2018 0.5× (16.82%)
FY2017 0.6× 53.77%

Quarterly newest first

Period Debt to equity Change
Sep 2026 0.6× (5.60%)
Jun 2026 0.7× 2.93%
Dec 2025 0.6× (2.53%)
Sep 2025 0.7× (0.75%)
30 more quarters

Against its own ten years

Low 0.3× High 1.1×
Ten-year median 0.7×
Current reading's percentile 50

Debt to equity against peers

Company Debt to equity
NBIX Neurocrine Biosciences, Inc. compare 0.0×
UTHR United Therapeutics Corporation compare 0.0×
VTRS Viatris Inc. compare 0.1×
RDY Dr. Reddy's Laboratories Ltd compare 0.2×
HLN Haleon PLC Sponsored ADR compare 0.5×
ELAN Elanco Animal Health Incorporated compare 0.6×
TAK Takeda Pharmaceutical Co. 0.6×
TEVA Teva Pharmaceutical Industries Ltd. compare 2.1×
ZTS Zoetis Inc. compare 2.9×
Drug Manufacturers Specialty & Generic industry median 0.0×
Healthcare sector median 0.0×
Market median 0.1×

What Debt to equity is

Debt to Equity Ratio shows how much a company relies on borrowed money compared with the money its shareholders have in the business.

(Long Term Debt (Total) + Current Part of Debt) ÷ Shareholders Equity (Total)

The full definition of Debt to equity →

More on TAK